Two Sigma Advisers
RGLS

Two Sigma Advisers’s Regulus Therapeutics RGLS Stock Holding History

Two Sigma Advisers’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,050
Closed -$51K – 2847
2022
Q1 		$51K Buy
17,050
+1,920
+13% +$5K ﹤0.01% 2588
2021
Q4 		$48K Buy
15,130
+13,940
+1,171% +$61.9K ﹤0.01% 2477
2021
Q3 		$8K Buy
+1,190
New +$8.72K ﹤0.01% 2417
2021
Q2 		– Sell
-84,260
Closed -$1.31M – 2653
2021
Q1 		$1.31M Buy
+84,260
New +$1.25M ﹤0.01% 1497

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers's RGLS Position: Q2 2022 in Review

Two Sigma Advisers sold out of Regulus Therapeutics (RGLS) in Q2 2022, closing a stake of 17,050 shares — an estimated $51K sold.

Two Sigma Advisers first reported a position in RGLS in Q1 2021 and held it in 4 quarters. The position peaked at $1.31M in Q1 2021. 27 funds tracked by Wall St. Rank hold RGLS as of Q2 2022.

  • Two Sigma Advisers reported no remaining Regulus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 17,050 Regulus Therapeutics shares in Q2 2022, an estimated $51K.
  • Two Sigma Advisers first reported a position in Regulus Therapeutics in Q1 2021 and held it in 4 quarters.
  • Two Sigma Advisers's Regulus Therapeutics position peaked at $1.31M in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.